INO 1400

Drug Profile

INO 1400

Alternative Names: hTERT DNA cancer vaccine - Inovio; INO-1400; Synthetic Consensus (SynCon®) DNA vaccine

Latest Information Update: 26 Nov 2016

Price : $50

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Abramson Cancer Center of the University of Pennsylvania; Inovio Pharmaceuticals; Mayo Clinic; Thomas Jefferson University; University of North Carolina; University of Pennsylvania; Wayne State University
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 18 Dec 2014 Phase-I clinical trials in Breast cancer, Lung cancer and Pancreatic cancer in USA (IM)
  • 24 Jul 2013 Final pharmacodynamics data from a preclinical study in Cancer released by Inovio Pharmaceuticals ,
  • 14 Nov 2012 Preclinical trials in Cancer in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top